NMPA clears Zai Lab’s COBENFY, rewriting the schizophrenia treatment playbook
Zai Lab’s COBENFY approved in China as a first-in-class schizophrenia treatment. Find out what this milestone means for psychiatry and pharma innovation.
Zai Lab’s COBENFY approved in China as a first-in-class schizophrenia treatment. Find out what this milestone means for psychiatry and pharma innovation.